ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 117 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $530,976 | -32.8% | 77,515 | +1.7% | 0.00% | – |
| Q2 2023 | $790,578 | +36.0% | 76,237 | +6.1% | 0.00% | – |
| Q1 2023 | $581,387 | -49.1% | 71,865 | -0.8% | 0.00% | – |
| Q4 2022 | $1,142,000 | -1.0% | 72,430 | -1.2% | 0.00% | – |
| Q3 2022 | $1,153,000 | +9.8% | 73,275 | -2.7% | 0.00% | – |
| Q2 2022 | $1,050,000 | -19.9% | 75,322 | -1.0% | 0.00% | – |
| Q1 2022 | $1,311,000 | +21.5% | 76,052 | +2.4% | 0.00% | – |
| Q4 2021 | $1,079,000 | -19.4% | 74,258 | +65.4% | 0.00% | -100.0% |
| Q1 2017 | $1,339,000 | +2.4% | 44,887 | -6.8% | 0.00% | 0.0% |
| Q4 2016 | $1,307,000 | – | 48,146 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |